UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended May 31, 2013
	For the quarterly period ended November 30, 2013
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from __________ to __________

000-53700
Commission File Number
CorTronix Biomedical Advancement Technologies Inc.
Cortronix Biomedical Advancement Technologies Inc.
(Exact name of registrant as specified in its charter)
Nevada	98-0515701
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
8200 N.W. 41st Street, Suite 145B, Doral, FL	33166
(Address of principal executive offices)	(Zip Code)
(786) 859-3585
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [ ] No [ X ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[ ]	Accelerated filer	[ ]

Non-accelerated filer	[ ]	Smaller reporting company	[X]
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

Yes [ ] No [ ]

APPLICABLE ONLY TO CORPORATE ISSUERS

~~287~~349,~~000~~500,000 shares of common stock issued and outstanding as of ~~July~~February 1928, ~~2013~~2014 (Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.)

~~CorTronix~~Cortronix Biomedical Advancement Technologies Inc.

TABLE OF CONTENTS

		Page
	PART I – Financial Information
Item 1.	Financial Statements	45
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	56
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	79
Item 4.	Controls and Procedures	79
	PART II – Other Information
Item 1.	Legal Proceedings	910
Item 1A.	Risk Factors	910
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	910
Item 3.	Defaults Upon Senior Securities	910
Item 4.	Mine Safety Disclosures	910
Item 5.	Other Information	910
Item 6.	Exhibits	1011
	Signatures	1112

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Reference is made in particular to the description of our plans and objectives for future operations, assumptions underlying such plans and objectives, and other forward-looking statements included in this report. Such statements may be identified by the use of forward-looking terminology such as “may,” “will,” “expect,” “believe,” “estimate,” “anticipate,” “intend,” “continue,” or similar terms, variations of such terms, or the negative of such terms. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. Such statements address future events and conditions concerning, among others, capital expenditures, earnings, litigation, regulatory matters, liquidity and capital resources, and accounting matters. Actual results in each case could differ materially from those anticipated in such statements by reason of factors such as future economic conditions, changes in consumer demand, legislative, regulatory and competitive developments in markets in which we operate, results of litigation, and other circumstances affecting anticipated revenues and costs, and the risk factors set forth under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended August 31, ~~2012~~2013 filed on ~~December~~February 1421, ~~2012~~2014.

In this Quarterly Report on Form 10-Q, references to “dollars” and “$” are to United States dollars and references to “we,” “us,” “Company,” “our” means CorTronix Biomedical Advancement Technologies Inc., unless otherwise indicated.

YOU SHOULD NOT PLACE UNDUE RELIANCE ON THESE FORWARD LOOKING STATEMENTS

The forward-looking statements made in this Quarterly Report on Form 10-Q relate only to events or information as of the date on which the statements are made in this Quarterly Report on Form 10-Q. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this report and the documents that we reference in this report, including documents referenced by incorporation, completely and with the understanding that our actual future results may be materially different from what we expect or hope.

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Article 210 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the three ~~and nine~~ month periods ended ~~May~~November 3130, 2013 are not necessarily indicative of the results that may be expected for the fiscal year ending August 31, ~~2013~~2014. For further information refer to the consolidated financial statements and footnotes thereto included in our Company’s Annual Report on Form 10-K for the fiscal year ended August 31, ~~2012~~2013.

	Page
Unaudited Consolidated Financial Statements
Consolidated Balance Sheets	F-1
Consolidated Statements of Operations	F-2
Consolidated Statement of Stockholders' Deficiency	F-3
Consolidated Statements of Cash Flows	F-3
Consolidated Statements of Cash Flows	F-4
Notes to Consolidated Financial Statements	F-4 to F-9
Notes to Consolidated Financial Statements	F-5 to F10

CORTRONIX BIOMEDICAL ADVANCEMENT TECHNOLOGIES INC.

(A Development Stage Company)

CONSOLIDATED BALANCE SHEETS

	May 31, 2013 (Unaudited)			August 31, 2012 (Audited)
	November 30, 2013 (Unaudited)			August 31, 2013
ASSETS
Current assets
Cash	$	21-		$	~~31,686~~640
Prepaid expenses		6660,~~981~~377			160,~~813~~377
Total current assets		6760,~~002~~377			3361,~~499~~017
Security deposit		3,390			3,390
Equipment and furniture, net		19,~~946~~300			620,~~690~~962
Total Assets	$	9083,~~338~~067		$	4385,~~579~~369
LIABILTIES AND STOCKHOLDERS’ DEFICIENCY
Current liabilities
Accounts payable and accrued liabilities	$	5345,~~171~~209		$	177,~~161~~625
Accounts payable – related parties		27,829			-
Accounts payable and accrued liabilities, related parties		72,077			28,827
Accrued interest		95136,~~819~~901			-116,473
Payroll liabilities		39,~~642~~943			29,~~604~~943
Advances from related parties		3489,~~358~~236			5085,~~000~~008
Notes payable		819,~~373~~374			-819,374
Total Current Liabilities		1,~~034~~172,~~192~~740			531,~~765~~137,250
STOCKHOLDERS’ DEFICIENCY
Common stock: 800,000,000 shares authorized, at $0.001 par value 287,000,000 and 175,000,000 shares issued and outstanding at May 31, 2013 and August 31, 2012, respectively		287,000			175,000
Common stock: 800,000,000 shares authorized, at $0.001 par value 349,500,000 and 287,000,000 shares issued and outstanding at November 30, 2013 and August 31, 2013, respectively		349,500			287,000
Capital in excess of par value		~~(888~~4,~~702~~048,798	)		(~~174~~888,~~250~~702	)
Deficit accumulated during the development stage		(~~342~~5,~~152~~487,971	)		(10450,~~936~~179	)
Total Stockholders’ Deficiency		(~~943~~1,~~854~~089,673	)		(101,~~186~~051,881	)
Total Liabilities and Stockholders’ Deficiency	$	9083,~~338~~067		$	4385,~~579~~369

The accompanying notes are an integral part of these ~~consolidated~~ financial statements.

F-1

CORTRONIX BIOMEDICAL ADVANCEMENT TECHNOLOGIES INC.

(A Development Stage Company)

CONSOLIDATED STATEMENTS OF OPERATIONS

For the three months ~~and nine months~~ ended ~~May~~November 3130, 2013 and 2012

and for the period from

August 3, 2012 (date of inception) to ~~May~~November 3130, 2013

	Three months ended May 31,			Nine months ended May 31,			August 3, 2012 (date of inception) to May 31,
	Three months ended November 30,						August 3, 2012 (date of inception) to November 30,
	2013			~~2013~~2012			2013
REVENUE	$	-		$	-		$	-
EXPENSES
Professional fees		~~4,141~~110			3712,~~744~~706			3743,~~744~~308
Patent fees		~~19,742~~-			~~19,742~~-			19,~~742~~792
Salary and wages		4443,~~905~~250			~~137~~43,~~296~~250			~~146~~236,~~911~~134
Depreciation		~~254~~1,662			~~763~~255			~~763~~2,679
Other general and administrative expenses		23,310			81,759			83,080
Marketing expenses		4,200,000			-			4,200,000
OPERATING LOSS		(92,352	)		(277,304	)		(288,240	)
Other general and administrative expenses		12,342			31,388			131,064
OPERATING LOSS		(4,257,364	)		(87,599	)		(4,632,977	)
Other income and expense
Interest expense		(20,~~290~~428	)		(5314,~~912~~624	)		(5394,~~912~~994	)
NET LOSS	$	(112,642	)	$	(331,216	)	$	(342,152	)
Loss on debt settlement		(760,000	)		-			(760,000	)
Basic and diluted loss per share	$	(0.00	)	$	(0.00	)
NET LOSS	$	(5,037,792	)	$	(102,223	)	$	(5,487,971	)
Weighted average number of shares outstanding, basic and diluted		287,000,000			282,487,179
Basic and diluted loss per share	$	(0.02	)	$	(0.00	)
Weighted average number of shares outstanding, basic and diluted		294,554,945			273,461,538

The accompanying notes are an integral part of these ~~consolidated~~ financial statements.

F-2

CORTRONIX BIOMEDICAL ADVANCEMENT TECHNOLOGIES INC.

(A Development Stage Company)

CONSOLIDATED ~~STATEMENT~~STATEMENTS OF ~~STOCKHOLDERS’~~CASH ~~DEFICIENCY~~FLOWS

For the ~~Period~~three ~~from~~months ~~August~~ended 3,November ~~2012 (date of inception) to May 31~~30, 2013 and 2012

								Accumulated
								Deficit
					Additional			During the
	Common Stock				paid-in			Development
	Shares		Amount		Capital			Stage			Total
Balance August 3, 2012		-	$	-	$	-		$	-		$	-
Issuance of common shares for cash, August 3, 2012		750,000		750		-			-			750
Recapitalization effect on issuance of common shares		174,250,000		174,250		(174,250	)		-			-
Net loss		-		-		-			(10,936	)		(10,936	)
Balance, August 31, 2012		175,000,000		175,000		(174,250	)		(10,936	)		(10,186	)
Recapitalization on September 11, 2012		112,000,000		112,000		(714,452	)		-			(602,452	)
Net loss for the period		-		-		-			(331,216	)		(331,216	)
Balance, May 31, 2013		287,000,000	$	287,000	$	(888,702	)	$	(342,152	)	$	(943,854	)

and for the period from August 3, 2012 (date of inception) to November 30, 2013

The accompanying notes are an integral part of these consolidated financial statements.

	Three Months ended November 30, 2013			Three Months ended November 30, 2012			From inception (August 3, 2012) to November 30, 2013

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(5,037,792	)	$	(102,223	)	$	(5,487,971	)
Adjustment to reconcile net loss to net cash (used in) operating activities:
Shares issued for marketing expenses		4,200,000			-			4,200,000
Loss on shares issued for settlement of accounts payable		760,000			-			760,000
Depreciation		1,662			255			2,679
Change in operating assets and liabilities:
Accrued interest		20,428			14,624			94,994
Damage deposit		-			-			(3,390	)
Prepaid expenses		-			(65,168	)		(60,377	)
Payroll liabilities		-			1,931			9,943
Advances from related party		4,228			-			54,878
Accounts payable and accrued liabilities		7,584			368			65,507
Accounts payable and accrued liabilities– related parties		43,250			4,000			72,077
Net cash provided by (used) in operating activities		(640	)		(146,213	)		(291,660	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of equipment and furniture		-			(8,938	)		(21,979	)
Cash from acquisition		-			-			22,889
Net cash provided by ( used) in investing activities		-			(8,938	)		910

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes		-			150,000			290,000
Proceeds from issuance of common stock		-			-			750
Net cash provided by financing activities		-			150,000			290,750

Increase (decrease) in cash during the period		(640	)		17,738			(640	)
Cash, beginning of period		640			31,686			640
Cash, end of period	$	-		$	49,424		$	-


Supplemental disclosure of non-cash investing activities:
Shares issued to settle accounts payable	$	40,000		$	-		$	40,000
Accounts payable acquired from reverse acquisition		-			-			19,702
Accrued interest acquired from reverse acquisition		-			-			41,907
Advances from related parties acquired from reverse acquisition		-			-			34,358
Notes payable acquired from reverse acquisition		-			-			579,373
Loan receivable		-			-			(50,000	)
	$	40,000		$	-		$	665,340

The accompanying notes are an integral part of these financial statements.

F-3

CORTRONIX BIOMEDICAL ADVANCEMENT TECHNOLOGIES INC.

(A Development Stage Company)

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the nine months ended May 31, 2013

and for the period from August 3, 2012 (date of inception) to May 31, 2013

	Nine Months ended May 31, 2013			From inception (August 3, 2012) to May 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(331,216	)	$	(342,152	)
Adjustment to reconcile net loss to net cash (used in) operating activities:
Depreciation		763			763
Accrued interest		53,912			53,912
Damage deposit		-			(3,390	)
Prepaid expenses		(65,168	)		(66,981	)
Payroll liabilities		1,038			3,642
Accounts payable and accrued liabilities		32,308			33,469
Accounts payable – related parties		27,829			27,829
Net cash provided by (used) in operating activities		(280,534	)		(292,908	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of equipment and furniture		(14,019	)		(20,709	)
Cash from acquisition		22,889			22,889
Net cash provided by ( used) in investing activities		8,870			2,180
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes		240,000			290,000
Proceeds from issuance of common stock		-			750
Net cash provided by financing activities		240,000			290,750
Increase (decrease) in cash during the period		(31,664	)		22
Cash, beginning of period		31,686			-
Cash, end of period	$	22		$	22
Supplemental non-cash investing activities:
Accounts payable acquired from reverse acquisition	$	19,702		$	19,702
Accrued interest acquired from reverse acquisition		41,907			41,907
Advances from related parties acquired from reverse acquisition		34,358			34,358
Notes payable acquired from reverse acquisition		579,373			579,373
Loan receivable		(50,000	)		(50,000	)
		625,340			625,340

The accompanying notes are an integral part of these consolidated financial statements.

F-4

CORTRONIX BIOMEDICAL ADVANCEMENT TECHNOLOGIES INC.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

~~May~~November 3130, 2013

1. ORGANIZATION AND BASIS OF PRESENTATON

CorTronix Biomedical Advancement Technologies Inc. (formerly Pana-Minerales S.A.) (the “Company”), was incorporated under the laws of the State of Nevada on October 4, 2006 with authorized capital stock of 100,000,000 shares at $0.001 par value. The Company was originally organized for the purpose of acquiring and developing mineral properties.

On August 15, 2012, we entered into an acquisition agreement with CorTronix Technologies Inc. (“CorTronix”). The officer and director of CorTronix, Yoel Palomino is also the officer and director of the Company, and is the developer of the technology held by CorTronix. CorTronix was incorporated solely for the purpose of this acquisition and its only operations were the development of a proprietary technology known as ~~CorlinkTM~~Corlink. ~~CorlinkTM~~Corlink, is an advanced telemetric system used to transmit, analyze, report and store all types and variations of physiological studies. Under the terms of the acquisition agreement CorTronix became a wholly owned subsidiary of the Company and is now the operational company which will continue with the commercialization of the technology it holds. Under the terms of the agreement, the Company acquired all of the issued and outstanding shares of CorTronix in exchange for the issuance of 175,000,000 restricted shares of the Company. The Share Exchange Agreement was completed on September 11, 2012.

The business combination was accounted for as a reverse acquisition and recapitalization using accounting principles applicable to reverse acquisitions whereby the financial statements subsequent to the date of the transaction are presented as a continuation of CorTronix. Under reverse acquisition accounting CorTronix (subsidiary) is treated as the accounting parent (acquirer) and the Company (parent) is treated as the accounting subsidiary (acquiree). All outstanding shares have been restated to reflect the effect of the business combination.

Both the Company and its subsidiary CorTronix have a fiscal year end of August 31.

The interim consolidated financial statements for the ~~nine~~three months ended ~~May~~November 3130, 2013 are unaudited. These consolidated financial statements are prepared in accordance with requirements for unaudited interim periods, and consequently do not include all disclosures required to be in conformity with accounting principles generally accepted in the United States of America. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the fiscal year ended August 31, ~~2013~~2014. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. These interim consolidated financial statements should be read in conjunction with the financial statements included in our Annual Report on Form 10-K for the year ended August 31, ~~2012~~2013 filed with the Securities and Exchange Commission on ~~December~~February 1421, ~~2012~~2014.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

These consolidated financial statements include the accounts of CorTronix Biomedical Advancement Technologies Inc., and its wholly-owned subsidiary, CorTronix Technologies Inc. All intercompany balances and transactions have been eliminated in consolidation.

FDevelopment-5 Stage

CorTronix Biomedical Advancement Technologies Inc. is a development-stage company as defined in Accounting Standards Codification (“ASC”) 915 Development-Stage Entities, as it is developing an advanced telemetric system used to transmit, analyze, report and store all types and variations of physiological studies. There have been no revenues from planned principal operations or sales from August 3, 2012 (date of inception) through to November 30, 2013. Consequently, cumulative amounts are presented in these consolidated financial statements.

Cash and Cash Equivalents

For purposes of the consolidated statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.

F-4

CORTRONIX BIOMEDICAL ADVANCEMENT TECHNOLOGIES INC.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

~~May~~November 3130, 2013

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Development- Stage

CorTronix Biomedical Advancement Technologies Inc. is a development-stage company as defined in Accounting Standards Codification (“ASC”) 915 Development-Stage Entities, as it is developing an advanced telemetric system used to transmit, analyze, report and store all types and variations of physiological studies. There have been no revenues from planned principal operations or sales from August 3, 2012 (date of inception) through to May 31, 2013. Consequently, cumulative amounts are presented in these consolidated financial statements.

Cash and Cash Equivalents

For purposes of the consolidated statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost. Depreciation and amortization of property and equipment are calculated using the straight-line method over the assets’ estimated useful lives as follows: computer hardware and software (three years), leasehold improvements (the shorter of five years or lease life), furniture and fixtures (five years) and equipment (~~five~~three to ten years).

Maintenance and repairs are charged to expense as incurred. Significant renewals and betterments are capitalized. At the time of retirement or other disposition of property and equipment, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations.

Research and Development

Research and development costs are expensed as incurred. The costs of materials and equipment that will be acquired or constructed for project development activities, and that have alternative future uses, both in project development, marketing or sales, will be capitalized classified as property, plant and equipment and depreciated over their estimated useful lives. To date, research costs, including amounts paid for man hours allocated to ongoing technology development, have been expensed when incurred.

Accounting Methods

The Company recognizes income and expenses based on the accrual method of accounting.

Dividend Policy

The Company has not yet adopted a policy regarding payment of dividends.

Basic and Diluted Net Income (loss) Per Share

Basic net income (loss) per share amounts are computed based on the weighted average number of shares actually outstanding. Diluted net income (loss) per share amounts are computed using the weighted average number of common and common equivalent shares outstanding as if shares had been issued on the exercise of any common share rights unless the exercise becomes antidilutive and then the basic and diluted per share amounts are the same.

~~F-6~~Income Taxes

The Company utilizes the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax bases of the assets and liabilities and are measured using the enacted tax rates and laws that will be in effect, when the differences are expected to reverse. An allowance against deferred tax assets is recorded, when it is more likely than not, that such tax benefits will not be realized. As of November 30, 2013, the Company had a deferred tax asset and related valuation allowance of $2,222,600, which begins to expire in 2032, related to its current operations.

Section 382 of the Internal Revenue Code imposes limitations on net loss carryforwards when there is a change in control. Due to the change of business and management, the Company has assumed loss carryforwards related to the Company’s prior operations will not be available to offset future taxable income.

F-5

CORTRONIX BIOMEDICAL ADVANCEMENT TECHNOLOGIES INC.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

~~May~~November 3130, 2013

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Income Taxes

The Company utilizes the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax bases of the assets and liabilities and are measured using the enacted tax rates and laws that will be in effect, when the differences are expected to reverse. An allowance against deferred tax assets is recorded, when it is more likely than not, that such tax benefits will not be realized. As of May 31, 2013, the Company had a deferred tax asset and related valuation allowance of $78,000, which begins to expire in 2032, related to its current operations.

Advertising and Market Development

The Company expenses advertising and market development costs as incurred.

Impairment of Long-lived Assets

The Company reviews and evaluates long-lived assets for impairment when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. The assets are subject to impairment consideration under ASC 360-10-35-17 if events or circumstances indicate that their carrying amounts might not be recoverable. When the Company determines that an impairment analysis should be done, the analysis will be performed using rules of ASC 930-360-35, Asset Impairment, and 360-10-15-3 through 15-5, Impairment or Disposal of Long-Lived Assets.

Financial Instruments

The carrying amounts of financial instruments are considered by management to be their fair value due to their short term maturities.

Estimates and Assumptions

Management uses estimates and assumptions in preparing financial statements in accordance with general accepted accounting principles. Those estimates and assumptions affect the reported amounts of the assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were assumed in preparing these financial statements.

Statement of Cash Flows

For the purposes of the statement of cash flows, the Company considers all highly liquid investments with a maturity of three months or less to be cash equivalents.

Recent Accounting Pronouncements

There are several new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”) which are not yet effective. Each of these pronouncements, as applicable, has been or will be adopted by the Company. As of ~~May~~November 3130, 2013, none of these pronouncements is expected to have a material effect on the financial position, results of operations or cash flows of the Company.

~~F-7~~3. GOING CONCERN

The Company will need additional working capital to service its debt, for ongoing operational expenses and to continue with the commercialization of its development stage technology, which raises substantial doubt about its ability to continue as a going concern. While management of the Company has developed a strategy, which it believes will accomplish this objective through additional loans and advances, equity funding, and long term financing, which will enable the Company to operate for the coming year, there can be no assurance that funds will be available to the Company if and when needed.

F-6

CORTRONIX BIOMEDICAL ADVANCEMENT TECHNOLOGIES INC.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

~~May~~November 3130, 2013

3. GOING CONCERN

4. PREPAID EXPENSES

The following table provides details of the Company’s prepaid expenses as of ~~May~~November 3130, 2013 and August 31, ~~2012~~2013:

	May 31, 2013		August 31, 2012
	November 30, 2013		August 31, 2013
Legal services fee	$	7,500	$	-
Advances to manufacturer		60,377		60,377
Rent		-		1,814
	$	60,377	$	60,377
Advances to manufacturer		59,481		-
	$	66,981	$	1,814

Prepaid expenses of $5960,~~481~~377 consist of amounts advanced to manufacturing firms with respect to the development of ~~CorlinkTM~~Corlink prototypes and manufacturing moulds. As at the date of this report certain of the moulds have been completed and during September 2013 the ~~Company~~prototype for CorTab was received, has beentested and is ~~expecting~~considered tomostly ~~receive~~functional ~~prototypes~~and ready for trials. The Company has made request for a statement of ~~its~~account ~~customized~~from ~~product~~the ~~line~~manufacturers in order to capitalize qualifying expenditures. As at the ~~next~~date 60of ~~days~~this report the requested statement has not yet been received.

~~A prepaid expense of $7,500 is the retainer for general IP consultation related to the development of Smartphone Apps for Remotely Monitoring and Reading ECG’s and Other Medical Devices~~5. ~~The~~ ~~retainer~~Property ~~is maintained during the course of the work performed by the IP consultants~~ and ~~will be applied to any final billings upon completion of work performed.~~equipment

5. BUSINESS COMBINATION

	November 30, 2013			August 31, 2013
Computer hardware and software	$	6,191		$	6,191
Testing equipment		10,701			10,701
Office furniture		5,087			5,087
Total		21,979			21,979
Accumulated depreciation		(2,679	)		(1,017	)
	$	19,300		$	20,962

~~On August 15, 2012, the Company entered into an acquisition agreement with CorTronix~~6. ~~The~~ ~~officer~~LEASE and director of CorTronix, Yoel Palomino is also the officer and director of the Company, and is the developer of the technology held by CorTronix. CorTronix was incorporated solely for the purpose of this acquisition and its only operations were the development of a proprietary technology known as CorlinkTM. CorlinkTM,is an advanced telemetric system used to transmit, analyze, report and store all types and variations of physiological studies. Under the terms of the acquisition agreement CorTronix became a wholly owned subsidiary of the Company and is now the operational company which will continue with the commercialization of the technology it holds. Under the terms of the agreement, the Company acquired all of the issued and outstanding shares of CorTronix in exchange for the issuance of 175,000,000 restricted shares of the Company. The Share Exchange Agreement was completed on September 11, 2012.AGREEMENT

~~CorTronix~~On ~~was~~August ~~incorporated~~22, ~~under~~2012, ~~the~~CorTronix ~~laws~~leased ofoffice ~~the~~space ~~State~~in ofHialeah, ~~Nevada~~Florida on ~~August~~a 3,one ~~2012~~year lease with ~~authorized~~monthly ~~capital~~rental ~~stock~~payments of 75$1,~~000,000~~814 ~~shares~~per atmonth ~~$0.001~~including ~~par~~applicable ~~value~~taxes. ~~CorTronix~~ The lease was ~~organized~~renewed ~~for~~during the ~~purpose~~year for a further term ending on August 22, 2014 with monthly rental payments of ~~developing~~$1,869 ~~the~~per ~~CorlinkTM~~month ~~technology~~including applicable taxes.

~~Pursuant~~Under to the terms ~~and conditions~~ of the ~~acquisition~~above ~~agreement~~noted lease, wethe ~~acquired~~Company ~~100%~~was ofrequired ~~the~~to ~~issued~~provide ~~capital~~a ~~stock,~~security ~~750~~deposit totaling $3,~~000~~990. ~~common~~The ~~shares;~~security ofdeposit ~~CorTronix~~is inheld ~~exchange~~by ~~for~~the ~~175,000,000~~Landlord ~~shares~~without interest and shall be applied by the Landlord on account of the ~~Company~~last month’s ~~common~~rent. ~~stock,~~The oramount ~~56.54%~~ is ~~the~~included ~~issued~~on ~~and~~the ~~outstanding~~balance ~~share~~sheet of the Company as "Security Deposit. "

~~F-8~~7. COMMITMENTS

On July 25, 2013, the Company entered into a marketing agreement with Global Investment Strategies S.A. LLC., a company with offices in Saudi Arabia (“GIS”) whereby GIS is granted the exclusive license for the Middle East and will provide support, management and personnel to make strategic introductions to end users of the Cortronix technologies, including but not limited to hospitals, government agencies, the military and certain airlines in the middle east and other countries. The Company is not requested to pay any payments, fees, royalties or other consideration other than to issue a total of 52,500,000 shares of the common stock of the Company which were issued on November 19, 2013. The contract also gives GIS the right to appoint a member to the Board of Directors; however, no appointment has yet been made. The agreement has an initial term of five years and renew automatically for an additional five years unless written notice is provided by either party.

F-7

CORTRONIX BIOMEDICAL ADVANCEMENT TECHNOLOGIES INC.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

~~May~~November 3130, 2013

57. ~~BUSINESS~~ ~~COMBINATION~~COMMITMENTS (continued)

On September 6, 2013, the Company entered into a consulting and investor relations agreement with Maplehurst Investment Group, LLC (“Maplehurst”). The ~~following~~Company ~~table~~had ~~summarizes~~previously during November 2012, engaged Maplehurst to provide consulting and investor relations services for a fee of $5,000 per month. Under the ~~estimated~~terms ~~fair~~of ~~values~~the new agreement, the Company agreed to settle the outstanding amount of $40,000 under the ~~assets~~contract ~~acquired~~with Maplehurst by way of the issuance of 10,000,000 shares of the common stock of the Company and ~~liabilities~~Maplehurst ~~assumed~~agreed atto provide services under the ~~business~~contract ~~combination~~for ~~transaction~~an ~~date:~~additional twelve month period for no further consideration. The shares were issued on November 19, 2013.

Cash and cash equivalents	$	22,889
Due from CorTronix		50,000
Total identifiable assets	$	72,889
Accounts payable	$	19,702
Accrued interest		41,907
Advances from related parties		34,358
Notes payable		579,373
Total identifiable liabilities	$	675,340
Net identifiable assets	$	(602,451	)

8. LOANS PAYABLE

6.A ~~LEASE~~summary ~~AGREEMENT~~of the principal balances of notes payable included in the consolidated balance sheet as of November 30, 2013:

On August 22, 2012, CorTronix leased office space in Hialeah, Florida on a one year lease with monthly rental payments of $1,814 per month including applicable taxes.

Date	Principal
April 15, 2011	$	50,000
May 6, 2011		50,000
May 26, 2011		31,000
September 30, 2011		49,798
October 5, 2011		3,903
November 5, 2011		8,570
November 7, 2011		50,000
January 10, 2012		1,995
March 12, 2012		21,320
March 27, 2012		200,000
April 5, 2012		6,214
April 10, 2012		100,000
July 6, 2012		6,573
November 9, 2012		150,000
February 4, 2013		50,000
April 2, 2013		40,000
	$	819,374

~~Under~~At ~~the~~November ~~terms~~30, of2013, ~~the~~there ~~above~~was ~~noted~~a ~~lease~~balance of $819, ~~the~~374 ~~Company~~outstanding, ~~was~~due ~~required~~and payable to ~~provide~~an aunrelated ~~security~~third ~~deposit~~party. These ~~totaling~~notes ~~$3,990.~~each ~~The~~have ~~security~~a ~~deposit~~one isyear ~~held~~term, bybearing ~~the~~interest ~~Landlord~~at ~~without~~ten ~~interest~~(10%) percent per annum and ~~shall~~are bepayable ~~applied~~in byfull on the ~~Landlord~~anniversary ondate. The ~~account~~accrued ofinterest for the ~~last~~three ~~month’s~~months ~~rent.~~period ended November 30, 2013 was $20,428 (November 30, 2012 - $14,624). The ~~amount~~Company isdid ~~included~~not onmake any payments towards accrued interest in the ~~balance~~period, ~~sheet~~leaving an amount of $136,901 (August 31, 2013 - $116,473) reflected on the Company’s balance sheet as ~~"Security~~Accrued ~~Deposit~~Interest."

7.Certain ~~LOANS~~of ~~PAYABLE~~these loans with a principal balance totaling $729,374 came due and payable in the current period at which time the lender verbally agreed to convert the loans to “demand” loans, with interest continuing to accrue until such time as they are paid in full.

~~A summary of the principal balances of notes payable included in the consolidated balance sheet as of May 31, 2013:~~F-8

Date	Principal
April 15, 2011	$	50,000
May 6, 2011		50,000
May 26, 2011		31,000
September 30, 2011		49,798
October 5, 2011		3,903
November 5, 2011		8,570
November 7, 2011		50,000
January 10, 2012		1,995
March 12, 2012		21,320
March 27, 2012		200,000
April 5, 2012		6,214
April 10, 2012		100,000
July 6, 2012		6,574
November 9, 2012		150,000
February 4, 2013		50,000
April 2, 2013		40,000
	$	819,374

F-9

CORTRONIX BIOMEDICAL ADVANCEMENT TECHNOLOGIES INC.

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

~~May~~November 3130, 2013

79. ~~LOANS~~SIGNIFICANT ~~PAYABLE~~TRANSACTIONS ~~(continued)~~WITH RELATED PARTIES

AtA ~~May~~former ~~31,~~officer ~~2013,~~and ~~there~~director ~~was~~and a11% ~~balance~~shareholder ofwas ~~$819, 374 outstanding,~~ due ~~and payable to~~ an ~~unrelated~~amount ~~third~~totaling ~~party. These notes each have a one year term~~$34,358 ~~bearing interest at ten~~ (~~10%)~~August ~~percent per annum and are payable in full on the anniversary date. The accrued interest for the nine month period ended May~~ 31, 2013 ~~totaled~~- $5334,~~912~~358) inwhich ~~respect~~amount ofbears ~~these~~no ~~loans. The Company did not make any payments towards accrued~~ interest ~~in the period~~, ~~leaving~~is anunsecured ~~amount~~and ofpayable ~~$95,819 reflected~~ on ~~the Company’s balance sheet as Accrued Interest~~demand.

~~Certain~~On ofAugust ~~these~~3, ~~loans~~2012, ~~with~~the Company entered into a ~~principal~~consulting ~~balance~~agreement ~~totaling~~with Mr. Yoel Palomino, director and officer of the Company. Under the terms of the agreement, the Company will pay an annual salary of $~~572~~125,~~800~~000 ~~came~~to ~~due~~Mr. ~~and~~Palomino, payable inweekly. During the ~~current~~three month period atended ~~which~~November ~~time~~30, 2013, the ~~lender~~Company ~~verbally~~accrued ~~agreed~~management tofees ~~convert~~of ~~the~~$31,250 ~~loans~~(November to30, ~~“demand”~~2012 ~~loans~~- $31,250). ~~with~~The ~~interest~~Company ~~continuing~~did not make any cash payments to ~~accrue~~Mr. ~~until~~Palomino ~~such~~in ~~time~~the asperiod, ~~they~~leaving ~~are~~$48,077 ~~paid~~(August in31, ~~full~~2013 – $16,827) due and payable to Mr. Palomino pursuant to the agreement.

8During the three month period ended November 30, 2013, Mr. ~~SIGNIFICANT~~Palomino ~~TRANSACTIONS~~further ~~WITH~~advanced ~~RELATED~~the ~~PARTY~~Company $4,228 in order to settle certain operating expenses payable as they came due. As of November 30, 2013, $54,878 (August 31, 2013 - $50,650) had been advanced by Mr. Palomino and was due for reimbursement.

OnDuring ~~August 3, 2012,~~ the ~~Company~~three ~~entered~~month ~~into~~period aended ~~consulting~~November ~~agreement~~30, ~~with~~2013, Mr. ~~Yoel~~Jorge ~~Palomino~~Saer, ~~director and officer of~~ the ~~Company.~~Chief ~~Under~~Technology ~~the~~Officer ~~terms~~ of the ~~agreement~~Company, ~~the~~invoiced ~~Company~~a ~~will~~total ~~pay~~amount ~~an annual salary~~ of $~~125~~12,000 to(November ~~Mr. Palomino~~30, ~~payable~~2012 ~~weekly.~~- ~~During~~$12,000) ~~the~~for ~~nine~~project ~~month~~development ~~period~~services. ~~ended~~The ~~May~~Company ~~31,~~did ~~2013,~~not ~~the~~make ~~Company~~any ~~made~~ cash payments ofto Mr. Saer, leaving $8124,~~731~~000 (August 31, ~~leaving~~2013 – $12,~~019~~000) due and payable to Mr. ~~Palomino~~ ~~pursuant~~Saer toas ~~the~~at ~~agreement~~November 30, 2013.

During the ~~nine~~three month period ended ~~May~~November 3130, 2013, ~~Mr.~~an ~~Palomino~~amount ~~advanced~~of $38,563 from the ~~Company~~salary ~~$510~~and inwage ~~order~~expenses for Yoel Palomino and Jorge Saer was attributed to ~~settle~~research ~~certain~~and ~~operating~~development ~~expenses~~with ~~payable~~respect asto ~~they~~the ~~came~~Company’s ~~due~~software currently under development.

~~During the nine month period ended May 31, 2013, Mr~~10. CAPITAL Jorge Saer, the Chief Technology Officer of the Company, invoiced a total amount of $36,000 for project development services. The Company made cash payments of $20,700, leaving $15,300 due and payable to Mr. Saer as at May 31, 2013.STOCK

~~During~~On ~~the~~August ~~nine~~15, ~~month~~2012, ~~period~~we ~~ended~~entered ~~May~~into ~~31,~~an ~~2013,~~acquisition anagreement ~~amount~~with Cortronix Technologies Inc. (“Cortronix”). Under the term of ~~$115~~the acquisition agreement,~~687~~ ~~from~~the Company acquired all of the ~~salary~~issued and ~~wage~~outstanding ~~expenses~~shares ~~for~~of ~~Yoel~~Cortronix ~~Palomino~~in ~~and~~exchange ~~Jorge~~for ~~Saer~~the ~~was~~issuance ~~attributed~~of to175,000,000 ~~research~~restricted ~~and~~shares ~~development~~of ~~with~~the ~~respect~~Company. toOn September 11, 2012, the Company’s ~~current~~completed ~~software~~this ~~currently~~transaction. All ~~under~~outstanding ~~development~~shares have been restated to reflect the effect of the business combination.

On ~~August~~November 1519, ~~2012~~2013, we ~~entered~~issued ~~into an acquisition agreement with CorTronix ( see Note 4 above)~~10, ~~a company controlled by our Officer and Director~~000,000 ~~Yoel~~shares ~~Palomino. Under the terms~~ of ~~the~~common ~~acquisition~~stock ~~agreement,~~at ~~the~~$0.001 ~~Company~~per ~~acquired~~share ~~all of the issued and outstanding shares of CorTronix~~ in ~~exchange~~settlement ~~for the issuance~~ of ~~175~~$40,000~~,000~~ ~~restricted~~due ~~shares of the Company~~ to MrMaplehurst. ~~Palomino~~(ref ~~who~~Note ~~directed~~7). The ~~the~~shares ~~issuance~~of ascommon tostock ~~122,500,000~~were ~~shares~~valued ~~issued~~at ~~to Mr~~$0.08 ~~Palomino~~per ~~and~~share, 52totaling $800,~~500,~~000, ~~shares~~the ~~issued~~fair tomarket ~~Mr.~~value ~~Saer. On~~of ~~September~~the ~~11,~~shares ~~2012,~~on the ~~Company~~date ~~completed~~of ~~this~~issuance. ~~transaction~~The ~~and~~excess ~~CorTronix~~value ~~became~~was arecorded ~~wholly-owned~~as ~~subsidiary~~a ofloss ~~the~~totaling ~~Company~~$760,000.

9On November 19, 2013, we issued a total of 52,500,000 shares of common stock to GIS. ~~CAPITAL~~(ref ~~STOCK~~Note 7) The shares of common stock were valued at $0.08 per share, totaling $4,200,000, the fair market value of the shares on the date of issuance. The value was recorded as marketing expense.

OnAs ~~August~~at ~~15,~~November ~~2012~~30, ~~we entered into an acquisition agreement with CorTronix. Under the term of the acquisition agreement~~2013, the Company ~~acquired~~had ~~all~~a oftotal ~~the issued and outstanding shares~~ of ~~CorTronix in exchange for the issuance of 175~~349,~~000~~500,000 ~~restricted~~ shares of ~~the~~common ~~Company.~~stock Onissued ~~September~~and ~~11, 2012, the Company completed this transaction. All~~ outstanding ~~shares have been restated to reflect the effect of the business combination~~.

~~As at May 31, 2013, the Company had a total of 287,000,000 shares of common stock issued and outstanding~~11. SUBSEQUENT EVENTS

10On December 30, 2013, the Company received funds in the amount of $15,500 from a third party. ~~SUBSEQUENT~~ ~~EVENTS~~The loan is a one-year unsecured promissory note with interest at a rate of 18% per 365 day period. After the maturity date, the note shall accrue interest at a rate of 18%, payable semi-annually, plus a penalty of 6% per 30 day period. Should the principal amount of the note and all accrued interest not be repaid within 30 days after the maturity date, the Company should pay a penalty in the form of shares of common stock equal to 18,750 shares per month pro-rated daily.

The Company has evaluated subsequent events from the balance sheet date through the date that the financial statements were issued and determined that there were no other events to disclose.

F-109

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

The Company was incorporated under the laws of the State of Nevada on October 4, 2006 with authorized capital stock of 100,000,000 shares at $0.001 par value. The Company was originally organized for the purpose of acquiring and developing mineral properties. The Company divested itself of all of its mining properties during 2012, upon finalizing the agreements with CorTronix Technologies Inc. CorTronix is a BioMedical corporation with a core competency in Mobile Cardio Devices. CorTronix™ is in development stages of creating a complete product line that will consist of what management believes to be revolutionary multiple mobile devices with the capacity to acquire and process patient's data through a consolidated “Single Source” Network.

On August 15, 2012, we entered into an acquisition agreement with CorTronix Technologies Inc. (“CorTronix”). Yoel Palomino, the sole officer and director of the Company is the developer of the technology held by CorTronix. CorTronix was incorporated solely for the purpose of this acquisition. The assets of CorTronix are CorlinkTM an advanced telemetric system used to transmit, analyze, report and store all types and variations of physiological studies. Under the terms of the agreement, the Company acquired all of the issued and outstanding shares of CorTronix in exchange for the issuance of 175,000,000 restricted shares of the common stock of the Company in exchange for all of the issued and outstanding shares of CorTronix. The transaction was completed on September 11, 2012.

The Company is developing the CorTronix technology through its wholly-owned subsidiary.

Results of Operations

~~The~~We ~~following~~have ~~discussion~~suffered ofrecurring ~~the~~losses ~~financial~~from ~~condition, results of~~ operations,. ~~cash~~The ~~flows,~~continuation ~~and~~of ~~changes in~~ our ~~financial~~Company ~~position~~is ~~should~~dependent beupon ~~read~~us inattaining ~~conjunction~~and ~~with~~maintaining ~~our~~profitable ~~audited~~operations ~~consolidated financial statements~~ and ~~notes~~raising ~~included~~additional incapital ~~our~~as ~~Annual Report on Form 10-K for the fiscal year ended August 31, 2012, filed on December 14, 2012~~needed.

WeDuring ~~have~~the ~~suffered~~three ~~recurring~~months ~~losses~~ended November 30, 2013 and November 30, 2012 we earned no revenues from operations. For ~~The~~the ~~continuation~~fiscal ofyear ~~our~~ended November ~~Company~~30, is2013 ~~dependent~~we ~~upon~~incurred uslosses ~~attaining~~from operations of $4,257,364 and ~~maintaining~~a ~~profitable~~net loss of $5,037,792 as compared to losses from operations of $87,599 and ~~raising~~a ~~additional~~net ~~capital~~loss of $102,223 for the three months ended November 30, 2012. The substantial increase in losses for the three months ended November 30, 2013 over the comparable period ended November 30, 2012 is related to the Company progressing its business and the entry into a marketing agreement whereby the Company issued shares which were valued at $0.08 as ~~needed~~of the date of issuance. InThe ~~this~~substantial ~~regard~~increase in operating losses for the three months ended November 30, we2013 ~~have~~is ~~successfully~~primarily ~~raised~~attributed ~~additional~~to ~~capital~~marketing ~~through~~expenses ~~loan~~in ~~transactions~~the amount of $4,200,000 related to the issuance of shares in consideration of a marketing agreement with no comparable expense in the ~~past~~period ended November 30, 2012/ Salaries and ~~presently~~wages ~~believe~~stayed weconstant ~~will~~period beover ~~able~~period at $43,250, professional fees decreased from $12,706 (November 30, 2012) to ~~raise~~$110 ~~additional~~at ~~funds~~November ~~through~~30, ~~loan~~2013, ~~transactions~~general and ~~equity~~administrative ~~offerings~~expenses inalso decreased from $31,388 (November 30, 2012) to $12,342 at November 30, 2013 while depreciation increased from $255 (November 30, 2012 to $1662 at November 30, 2013. Not taking into account the ~~future~~expense of $4,200,000 ~~though~~our weexpenses ~~can~~for ~~offer~~operations nodecreased ~~assurance~~from $87,599 for the period ended November 30, 2012 to $57,374 at November 30, 2013. Our net loss includes an interest expense of ~~this~~$20,428 ~~outcome~~for the three months ended November 30, 2013 as compared to an interest expense of $14,624 for the comparable period ended November 30, 2012 and a loss on debt settlement of $760,000 for the three months ended November 30, 2013 with no ~~specific~~comparable ~~arrangements~~loss ~~are~~for the three months ended November 30, 2012. The $760,000 was due to the issuance of shares in ~~place~~settlement of $40,000 debt with the 10,000,000 shares being valued at $0.08 per share.

~~The~~Period ~~three~~from ~~month~~inception, ~~period~~August ~~ended~~3, ~~May~~2012 31to November 30, 2013

~~During~~Our ~~the~~revenues ~~three~~since ~~month~~inception ~~period~~to ~~ended~~date ~~May~~have 31been $nil. Since inception, losses from operations have totaled $4,632,977 and we ~~earned~~have nonet ~~revenues~~loss ~~from~~of ~~operations~~$5,487,971. We expect to continue to incur losses as a result of continued research and development expenses for our technology, marketing and manufacturing expenses and as a result of expenditures for general and administrative activities while we remain in the development stage.

~~The Company completed a reverse merger with an inception date of August 3, 2012 and therefore there is no comparable data for the three months ended May 31, 2012.~~6

For the three month period ended May 31, 2013 we incurred losses from operations of $92,352 and a net loss of $112,642. The operating loss for the period ended May 31, 2013 is primarily attributed to salaries and wages of $44,905, professional fees of $4,141, patent fee of $19,742 and general and administrative expenses of $23,310. All related to our business operations. Our net loss includes an interest expense of $20,290 on loans for operations.

The nine month period ended May 31, 2013

During the nine month period ended May 31, 2013 we earned no revenues from operations.

The Company completed a reverse merger with an inception date of August 3, 2012 and therefore there is no comparable data for the nine months ended May 31, 2012.

For the nine month period ended May 31, 2013 we incurred and operation loss of $277,304 and a net loss of $331,216. The operating loss for the period ended May 31, 2013 is primarily attributed to salaries and wages of $137,296, professional fees of $37,744, patent fee of $19,742 and general and administrative expenses of $81,759. The net loss includes incurred interest of $53,912 on loans for operations.

Period from inception, August 3, 2012 to May 31, 2013

Our revenues since inception to date have been $nil. Since inception, losses from operations have totaled $288,240 and we have an accumulated deficit of $342,152 due to the operating losses of $256,498 and interest expenses of $53,912. We expect to continue to incur losses as a result of continued research and development expenses for our technology, marketing and manufacturing expenses and as a result of expenditures for general and administrative activities while we remain in the development stage.

Liquidity and Capital Resources

As of ~~May~~the three months ended November 30, 2013 we had no cash, prepaid expenses of $60,377 and a working capital deficiency of $1,112,360as compared to our fiscal year ended August 31, 2013, when we had approximately $22640 in cash, prepaid expenses of $6660,~~981~~377 and a working capital deficiency of $~~967~~1,~~190.~~ 076,233 During the ~~nine~~three months ended ~~May~~November 3130, 2013, we used net cash of $~~280,534~~640 in operating activities compared to $146,213 during the three months ended November 30, 2012.

During the ~~nine~~three months ended ~~May~~November 3130, ~~2013~~2012, we received $~~240~~150,000 by way of loans from an unrelated third party in order to fund operations~~. The~~ ~~loans~~with ~~are~~no ~~unsecured,~~comparable ~~bear~~loans ~~interest~~received atfor ~~10%~~the ~~per~~period ~~annum~~ended November 30, ~~and~~2013. While ~~are~~the ~~due~~Company ~~one~~has ~~year~~been receiving funding from ~~the~~loans ~~date~~and offrom ~~advance.~~related ~~Interest~~party ~~shall~~advances ~~accrue~~we ~~during~~have ~~the~~not ~~term~~received ofsufficient ~~the~~funds ~~loans~~to ~~and~~meet isour ~~payable~~obligations onas ~~the~~they ~~due~~become ~~date~~due. This ~~Thus~~lack ~~the~~of ~~Company~~available ~~continues~~funding towhen ~~receive~~needed ~~loans~~has ~~for~~impacted ~~operations~~not ~~which~~only ison ~~allowing~~ the development ~~Company~~of our business but on our ability to meet ~~its~~our filing obligations aswith ~~they~~the ~~become~~requisite ~~due~~regulatory authorities. ~~However,~~There ~~there~~ can be no assurance that ~~such~~we ~~loans~~ will ~~continue~~be orable ~~will~~to beraise ~~available~~funding ifwhen required and ~~when~~we ~~needed~~may onnot abe ~~timely~~able ~~basis~~to continue operations. The Company intends to seek additional funding by way of loans or equity financings.

We will not have sufficient funds for our planned operations or to meet ongoing obligations unless we are successful in raising additional capital. Unless the Company can raise additional funds it will not be able to be able to continue to meet its filing requirements when they come due. Further, it will not have any funding with which to continue to further the development and marketing of its proprietary technologies. This could mean a loss of your investment.

~~During~~We anticipate that we will require a minimum of $1,500,000 over the ~~nine~~next twelve months ~~ended~~in ~~May~~order 31to finalize the R&D on the majority of our products and to maintain public company operations and to pay our outstanding liabilities. The Company believes that $600,000 ~~2013~~would be sufficient funding if it did not have to repay its outstanding loans. In that twelve month period we anticipate that we will have 4 out of 5 prototypes completed and in the approval process while continuing development of the final products. We are allocating a total of $183,000 for remaining R&D for the upcoming 12 months; however we ~~used~~may ~~net~~not ~~cash~~expend the entire R&D budget over the twelve month period as it is dependent on the timelines for development of each product. During the fiscal year ended November 30, 2013, an amount of $14154,~~019~~250 infrom ~~investing~~salaries ~~activities~~and ~~related~~consulting fees paid or accrued to Yoel Palomino and Jorge Saer was designated as R&D expenditures. Following is an updated review of the ~~purchase~~status of ~~equipment~~the ~~and~~Company’s ~~furniture~~technology as of the date of this filing. There has been no change in status from the information as provided in the Company’s Form 10-K filed on February 21, 2014.

We anticipate that we will require a minimum of $310,000 over the next twelve months in order to finalize the R&D on the majority of our products and to maintain public company operations. In that twelve month period we anticipate that we will have 4 out of 5 prototypes completed and in the approval process while continuing development of the final products. We are allocating a total of $210,000 for remaining R&D for the upcoming 12 months; however we may not expend the entire R&D budget over the twelve month period as it is dependent on the timelines for development of each product. During the nine month period ended May 31, 2013, an amount of $115,687 from salaries and consulting fees paid or accrued to Yoel Palomino and Jorge Saer was designated as R&D expenditures. Following is an updated review of the status of the Company’s technology as of the date of this filing. To compare with prior status please refer to the Company’s filings on its Form 10K for the period ended August 31, 2012.

CorLink&CorView:

9099% complete

The cloud system is 7598% complete, as the mechanism for sending and receiving studies is implemented with email notification along with the User management and security protocols. The mobile application is also 99-100% complete allowing for users to capture, analyze, process, manage and send 12 lead high resolution ECGs.

Cost to completion between $105,000 and $30,000 for FDA approvals and medical trials. This amount does not include marketing or sales costs which are not yet determined. For the purposes of our funding requirements we have used $30,000 for completion costs, but have not impacted any marketing or sales costs as those will be determined once the medical trials and FDA approvals have been received.

CorTab:

9099% complete

From the date of acquisition of the project the Company has migrated from an embedded ECG solution to a Bluetooth based solution through the R&D process. ~~Prototype~~A ~~circuits~~prototype, ~~are~~fully ~~due~~functional toUnit beis ~~received~~being intested ~~within~~at the ~~next~~moment 60on ~~days~~patients. The ~~from~~advanced ~~Rapid~~tablet ~~PCB,~~prototype awas ~~company~~received ~~dedicated~~from toour ~~rapid~~manufacturer ~~prototying~~in ~~of circuits~~China. As ~~well~~The ~~the~~Bluetooth ~~Company~~patient ~~expects~~acquisition ~~during~~module ~~the~~was, ~~upcoming~~manufactured ~~quarter~~and toassembled ~~receive prototype~~in-house ~~devices~~at ~~from~~the ~~Noble~~Cortronix ~~Win~~headquarters. ~~Internal~~Arrangements ~~based~~have inbeen ~~China.~~made ~~Cost~~ to ~~completion~~begin ~~$15,000~~production once orders are received.

~~CorPak~~During September 2013 the prototype for CorTab was received and tested and is mostly functional, ready for trials.

~~49%~~Testing ~~complete~~costs fall within the Corview costs, defined above and the product will require FDA approvals and medical trials.

The Company has selected the main device and platform to be used for the CorPak device. TheUSB embedded circuit is under testing currently, and is functioning properly. Tests continue to be implemented to bring about the definitive copy of the electrical schematic to remit to Noble Win International in China for implementation into the main device.7

CorPak:

60%complete

The Company has selected the main device and platform to be used for the CorPak device. Testing on the main circuit has been successful, and is functioning properly. Tests continue to be implemented to bring about the definitive copy of the electrical schematic to remit to Noble Win International in China for implementation into the main device. Hardware designs have also been developed to provide an idea of how the device will ultimately look.

Cost to completion $48,000

CorCare:

40% complete.

This technology uses platform protocols in common with our other units, therefore the work on the other units can be directly implemented with CorCare thus furthering the development of this technology.

Cost to completion $50,000

CorCheck:

42% complete.

This technology is similar to CorCare in that they both use the same platform. Work on the previous platforms can therefore also be adopted for CorCheck. Research on the duel cells used for alcohol detection in breath is being done as well as finger print analysis.

Cost to completion $55,000

~~CorCare~~Total R&D funding: $183,000

~~35%~~We ~~complete. This~~do ~~technology~~not ~~uses~~presently ~~platform~~have ~~protocols~~sufficient infunds ~~common~~to ~~with~~undertake our ~~other~~plan ~~units,~~of ~~therefore~~operations. ~~the~~We ~~work~~intend onto raise these funds by the ~~other~~sale ~~units~~of equity or loans as they can be ~~directly~~negotiated. ~~implemented~~We ~~with~~do ~~CorCare~~not ~~thus~~currently ~~furthering~~have any sources for equity funding and we cannot predict whether we will be able to negotiate any loans or raise the ~~development~~funding ofrequired ~~this~~to ~~technology~~undertake our business plan.

Cost to completion $60,000

CorCheck

30% complete. This technology is similar to CorCare in that they both use the same platform. Work on the previous platforms can therefore also be adopted for CorCheck.

Cost to completion $70,000

Total R&D funding: $210,000

We do not presently have sufficient funds to undertake our plan of operations. We believe we have sufficient funds to maintain the public company reporting status but will need to raise funds in order to undertake our business plan. We intend to raise these funds by the sale of equity or loans as they can be negotiated. We do not currently have any sources for equity funding and while we have been successful in raising funding by way of loans to date, we cannot predict whether we will be able to raise the funding required to undertake our business plan.

Our ability to continue operations will be dependent upon the successful completion of additional long-term or permanent equity financing, the support of creditors and shareholders, and, ultimately, the achievement of profitable operations. There can be no assurances that we will be successful, which would in turn significantly affect our ability to be successful in our new business plan. If not, we will likely be required to reduce operations or liquidate assets. We will continue to evaluate our projected expenditures relative to our available cash and to seek additional means of financing in order to satisfy our working capital and other cash requirements.

Critical Accounting Policies and Estimates

The preparation of our financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments which are based on historical experience and on various other factors that are believed to be reasonable under the circumstances. The results of their evaluation form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions and circumstances. Our significant accounting policies are more fully discussed in the Notes to our Financial Statements.

Off-Balance Sheet Arrangements

The Company does not presently have any off-balance sheet arrangements.

Critical Accounting Policies and Estimates

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

Not Applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

~~The~~ Our ~~Company~~management ~~has~~is ~~adopted~~responsible for establishing and ~~maintains~~maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that ~~are~~is designed to ~~provide~~ensure ~~reasonable assurance~~ that information required to be disclosed by us in the reports ~~filed~~that ~~under~~we ~~the~~file ~~Securities~~or ~~Exchange~~submit ~~Act~~under ~~of 1934, as amended (~~the “Exchange Act~~”),~~ ~~such as this Form 10-Q,~~ is ~~collected,~~ recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules ofand ~~the~~forms. ~~Securities~~Disclosure controls and ~~Exchange~~procedures ~~Commission. The~~include, ~~Company’s~~without ~~disclosure~~limitation, controls and procedures ~~are also~~ designed to ensure that ~~such~~ information isrequired ~~accumulated and communicated~~ to ~~management~~be todisclosed ~~allow~~by ~~timely~~an ~~decisions~~issuer ~~regarding~~in ~~required~~the ~~disclosure. As~~reports ~~required~~that ~~under~~it ~~Rule~~files ~~13a-15~~or ofsubmits under the Exchange Act, is accumulated and communicated to the ~~Company~~issuer’s management, including ~~the~~its ~~Chief~~principal ~~Executive~~executive ~~Officer~~officer ~~and~~or ~~Principal~~officers ~~Financial~~and ~~Officer,~~principal ~~has~~financial ~~conducted~~officer anor ~~evaluation~~officers, ofor ~~the~~persons ~~effectiveness~~performing ofsimilar ~~disclosure~~functions, ~~controls and procedures~~ as ofappropriate ~~the~~to ~~end~~allow oftimely ~~the~~decisions ~~period~~regarding ~~covered~~required ~~by this report~~disclosure.

~~Based~~An ~~upon~~evaluation ~~its~~was ~~current~~conducted ~~evaluation,~~under the ~~Company~~supervision ~~has~~and ~~concluded~~with ~~that~~the participation of our management of the ~~Company’s~~effectiveness ~~current~~of the design and operation of our disclosure controls and procedures ~~are~~as of November 30, 2013. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed ~~by the Company~~ in the reports that ~~the~~we ~~Company~~file ~~files~~ or ~~submits~~submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in ~~the~~ SEC’s rules and forms~~, and that such information is accumulated and communicated to the Company’s management, including the Company’s CEO, as appropriate, to allow timely decisions regarding required disclosure~~.

Management’s Report on Internal Control over Financial Reporting

The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15 of the Exchange Act. The Company’s internal control over financial reporting is designed to provide reasonable assurance to the Company’s management and Board of Directors regarding the preparation and fair presentation of published financial statements. Management conducted an assessment of the Company’s internal control over financial reporting based on the framework and criteria established by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control – Integrated Framework. Based on the assessment, management concluded that, as of May 31, 2013 the Company’s internal control over financial reporting is not effective. The assessment identified a material weakness in the internal control over financial reporting resulting from the Company not having adequate resources to employ sufficient personnel to provide adequate segregation of duties and have personnel knowledgeable in accounting and reporting.

The Company’s management, including its Chief Executive Officer and Principal Financial Officer, does not expect that the Company’s disclosure controls and procedures and its internal control processes will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of error or fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that the breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

Changes in Internal Control

There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the three months ended ~~May~~November 3130, 2013, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

This quarterly report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to rules of the Securities and Exchange Commission, which permanently exempt smaller reporting companies. 9

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

~~To the best of management’s knowledge, there are no material legal proceedings pending against the Company.~~None

ITEM 1A. RISK FACTORS

~~Not~~A ~~Applicable~~smaller reporting company is not required to provide the information required by this Item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

~~None.~~Unregistered Sales of Equity Securities

There were no unregistered securities sold or issued by the Company without the registration of these securities under the Securities Act of 1933 in reliance on exemptions from such registration requirements, within the period covered by this report, which have not been previously included in a Quarterly Report on Form 10-Q or a Current Report on Form 8-K.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY ~~DISCLOSURE~~DISCLOSURES

Not ~~applicable.~~Applicable

ITEM 5. OTHER INFORMATION

The Company is currently negotiating a partnership agreement with Saudi Global Investments LLC., a company duly incorporated in the Kingdom of Saudi Arabia with offices located in Riyadh, Saudi Arabia, regarding their intent to form a partnership in order to sell CorTronix products in the Middle-East and other countries. The parties had expected to finalize a formal agreement prior to the end of this quarter ended May 31, 2013, however, to date, no formal agreement has been finalized. The Company continues to work to complete a formal agreement.None

Item 6. Exhibits

EXHIBITS

Number	Description
3.1(a)	Articles of Incorporation.	Incorporated by reference to the Company’s Form S-1 registration statement filed with the Securities and Exchange Commission on October 14, 2008.
3.1(b)	Amendment to Articles of Incorporation	Incorporated by reference to the Company’s Current Report on Form 8-K filed on September 9, 2011.
3.1(c)	Amendment to Articles of Incorporation	Incorporated by reference to the Company’s Definitive 14C filed on November 2, 2012
3.2(a)	Bylaws.	Incorporated by reference to the Company’s Form S-1 registration statement filed with the Securities and Exchange Commission on October 14, 2008.
3.2(b)	Amendment to Bylaws	Incorporated by reference to the Company’s Current Report on Form 8-K filed on September 28, 2011.
10.1	Consulting Services and Finders Fee Agreement, dated February 1, 2012	Incorporated by reference to the Company’s Current Report on Form 8-K filed on February 1, 2012.
10.2	Mining Option Agreement, dated February 1, 2012	Incorporated by reference to the Company’s Current Report on Form 8-K filed on February 1, 2012.
10.3	Mutual Release Agreement by and between the Company and David Gibson	Incorporated by reference to the Company’s Form 10-K annual report filed with the Securities and Exchange Commission on December 14, 2011.
10.4	Form of Promissory Note	Incorporated by reference to the Company’s Form 10-K annual report filed with the Securities and Exchange Commission on December 14, 2011.
10.5	Acquisition Agreement between the Company and CorTronix dated August 15, 2012	Incorporated by reference to the Company’s Current Report on Form 8-K filed on August 21, 2012.
10.6	Assignment Agreement between Yoel Palomino and CorTronix dated August 10, 2012	Incorporated by reference to the Company’s Current Report on Form 8-K filed on August 21, 2012.
31.1	Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith
31.2	Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed herewith

101.INS	XBRL Instance Document	Filed herewith*
101.SCH	XBRL Taxonomy Extension Schema	Filed herewith*
101.CAL	XBRL Taxonomy Extension Calculation Linkbase	Filed herewith*
101.DEF	XBRL Taxonomy Extension Definition Linkbase	Filed herewith*
101.LAB	XBRL Taxonomy Extension Label Linkbase	Filed herewith*
101.PRE	XBRL Taxonomy Extension Presentation Linkbase	Filed herewith*

*Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability.

ITEM 6. EXHIBITS

Number	Description
3.1(a)	Articles of Incorporation.	Incorporated by reference to the Company’s Form S-1 registration statement filed with the Securities and Exchange Commission on October 14, 2008.
3.1(b)	Amendment to Articles of Incorporation	Incorporated by reference to the Company’s Current Report on Form 8-K filed on September 9, 2011.
3.1(c)	Amendment to Articles of Incorporation	Incorporated by reference to the Company’s Definitive 14C filed on November 2, 2012
3.2(a)	Bylaws.	Incorporated by reference to the Company’s Form S-1 registration statement filed with the Securities and Exchange Commission on October 14, 2008.
3.2(b)	Amendment to Bylaws	Incorporated by reference to the Company’s Current Report on Form 8-K filed on September 28, 2011.
10.1	Consulting Services and Finders Fee Agreement, dated February 1, 2012	Incorporated by reference to the Company’s Current Report on Form 8-K filed on February 1, 2012.
10.2	Mining Option Agreement, dated February 1, 2012	Incorporated by reference to the Company’s Current Report on Form 8-K filed on February 1, 2012.
10.3	Mutual Release Agreement by and between the Company and David Gibson	Incorporated by reference to the Company’s Form 10-K annual report filed with the Securities and Exchange Commission on December 14, 2011.
10.4	Form of Promissory Note	Incorporated by reference to the Company’s Form 10-K annual report filed with the Securities and Exchange Commission on December 14, 2011.
10.5	Acquisition Agreement between the Company and Cortronix dated August 15, 2012	Incorporated by reference to the Company’s Current Report on Form 8-K filed on August 21, 2012.
10.6	Assignment Agreement between Yoel Palomino and Cortronix dated August 10, 2012	Incorporated by reference to the Company’s Current Report on Form 8-K filed on August 21, 2012.
10.7	Consulting and Investor Relations Agreement between the Company and Maplehurst Investment Group LLC dated September 6, 2013	Incorporated by reference to the Company’s Current Report on Form 10-K filed on February 21, 2014.
10.8	Marketing Agreement between the Company and Global Investments Strategies SA LLC dated July 25, 2013	Incorporated by reference to the Company’s Current Report on Form 10-K filed on February 21, 2014.
31.1	Section 302 Certification- Principal Executive Officer	Filed herewith
31.2	Section 302 Certification- Principal Financial Officer	Filed herewith
32.1+	Certification Pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed herewith
101.INS++	XBRL Instance Document	Filed herewith
101.SCH++	XBRL Taxonomy Extension Schema	Filed herewith
101.CAL++	XBRL Taxonomy Extension Calculation Linkbase	Filed herewith
101.DEF++	XBRL Taxonomy Extension Definition Linkbase	Filed herewith
101.LAB++	XBRL Taxonomy Extension Label Linkbase	Filed herewith
101.PRE++	XBRL Taxonomy Extension Presentation Linkbase	Filed herewith

+The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Cortronix Biomedical Advancement Technologies Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

†† XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and is otherwise not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		CORTRONIX BIOMEDICAL ADVANCEMENT TECHNOLOGIES INC.
Date:	~~July~~March 223, ~~2013~~2014	By:	/s/ Yoel Palomino
		Name:	Yoel Palomino
		Title:	Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer and Director (Principal Executive Officer, Principal Financial and Principal Accounting Officer)

1112

Filing Compare · Cortronix Biomedical Advancement Technologies Inc.